The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...
Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers in a ...
The FDA’s Office of Prescription Drug Promotion sent Travere Therapeutics a letter over its advertising for Filspari, a drug that’s approved to slow kidney function decline in people with primary IgA ...
VegFest Kelowna returns to City Park in downtown Kelowna on Sunday, Sept. 20. It brings together local businesses, food ...
Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies / AbbVie Oncology, Asud ...
Investor's Business Daily on MSN
TGTX stock outperforms 95% of stocks. Here's why.
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics today and set a price target of $80.00. Unlock powerful investing tools with TipRanks Premium to make smarter, more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results